Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash & Equivalents (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Cash & Equivalents data on record, last reported at $42.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 4.26% year-over-year to $42.6 million; the TTM value through Sep 2025 reached $42.6 million, up 4.26%, while the annual FY2024 figure was $21.9 million, 41.33% up from the prior year.
  • Cash & Equivalents reached $42.6 million in Q3 2025 per CTNM's latest filing, up from $20.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $77.2 million in Q2 2024 and bottomed at $15.5 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $32.2 million, with a median of $22.2 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 41.33% in 2024, then tumbled 73.09% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $15.5 million in 2023, then skyrocketed by 41.33% to $21.9 million in 2024, then surged by 94.29% to $42.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $42.6 million in Q3 2025, $20.8 million in Q2 2025, and $22.5 million in Q1 2025.